Proton pump inhibitor therapy and hip fracture risk [1]

JAMA

Volumn 297, Issue 13, 2007, Pages 1429-

  Geller, Jordan L ^a   Adams, John S ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PROTON PUMP INHIBITOR; VITAMIN D; ANTIULCER AGENT; ENZYME INHIBITOR; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE;

BONE MINERALIZATION; CALCIUM TRANSPORT; HIP FRACTURE; HUMAN; LETTER; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; RISK FACTOR; VITAMIN BLOOD LEVEL; BONE DENSITY; DRUG ANTAGONISM; METABOLISM; NOTE; VITAMIN D DEFICIENCY;

ANTI-ULCER AGENTS; BONE DENSITY; ENZYME INHIBITORS; H(+)-K(+)-EXCHANGING ATPASE; HIP FRACTURES; HUMANS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 34047206794     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Streeten EA, Mohamed A, Gandhi A, et al. The inpatient consultation approach to osteoporosis treatment in patients with a fracture: is automatic consultation needed? J Bone Joint Surg Am. 2006;88:1968-1974.
2. Painter SE, Kleerekoper M, Camacho PM. Secondary osteoporosis: a review of the recent evidence. Endocr Pract. 2006;12:436-444.
3. Yang Y-X, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture [published correction appears in JAMA. 2007;297:470]. JAMA. 2006;296:2947-2953.
4. Holick MF. The role of vitamin D for bone health and fracture prevention. Curr Osteoporos Rep. 2006;4:96-102.
5. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001;22:477-501.